U.S. markets closed

AlloVir, Inc. (ALVR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
36.56-3.64 (-9.05%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close40.20
Open40.54
Bid37.00 x 1200
Ask41.00 x 900
Day's Range35.87 - 41.73
52 Week Range18.15 - 48.96
Volume265,892
Avg. Volume280,191
Market Cap2.264B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference
    Business Wire

    AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference

    AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021 at 4:20 p.m. ET.

  • AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
    Business Wire

    AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

    AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced results of a subgroup analysis from a Phase 2, proof-of-concept study (CHARMS) evaluating the company’s lead product candidate, Viralym-M (ALVR105), an allogeneic, off-the-shelf, multi-virus specific investigational T-cell therapy (VST), in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients with virus-associated hemorrhagic cystitis (V-HC). These data are being presented in an oral presentation during the Transplantation & Cellular Therapy (TCT) Meeting of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). Additionally, two separate oral presentations characterize the high economic and clinical burden of V-HC and double-stranded (ds) DNA viral infections in allo-HSCT recipients. Preclinical data was also presented in a poster presentation on ALVR109, AlloVir’s virus-specific T-cell therapy targeting SARS-CoV-2, the virus responsible for COVID-19.

  • AlloVir Reports Full Year 2020 Financial Results
    Business Wire

    AlloVir Reports Full Year 2020 Financial Results

    AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today provided a corporate update and reported full-year 2020 financial results for the period ended December 31, 2020.